225 related articles for article (PubMed ID: 16616962)
21. Synthesis, anti-HIV-1 activity, and modeling studies of N-3 Boc TSAO compound.
Tomassi C; Nguyen VN; Marco-Contelles J; Balzarini J; Pannecouque C; De Clercq E; Soriano E; Postel D
Bioorg Med Chem Lett; 2008 Apr; 18(7):2277-81. PubMed ID: 18353641
[TBL] [Abstract][Full Text] [Related]
22. First synthesis and evaluation of the inhibitory effects of aza analogues of TSAO on HIV-1 replication.
Nguyen Van Nhien A; Tomassi C; Len C; Marco-Contelles JL; Balzarini J; Pannecouque C; De Clercq E; Postel D
J Med Chem; 2005 Jun; 48(13):4276-84. PubMed ID: 15974581
[TBL] [Abstract][Full Text] [Related]
23. Design and discovery of a novel dipeptidyl-peptidase IV (CD26)-based prodrug approach.
García-Aparicio C; Bonache MC; De Meester I; San-Félix A; Balzarini J; Camarasa MJ; Velazquez S
J Med Chem; 2006 Aug; 49(17):5339-51. PubMed ID: 16913724
[TBL] [Abstract][Full Text] [Related]
24. Design of non-nucleoside inhibitors of HIV-1 reverse transcriptase with improved drug resistance properties. 1.
Hopkins AL; Ren J; Milton J; Hazen RJ; Chan JH; Stuart DI; Stammers DK
J Med Chem; 2004 Nov; 47(24):5912-22. PubMed ID: 15537346
[TBL] [Abstract][Full Text] [Related]
25. Novel 3'-spiro nucleoside analogues of TSAO-T. Part II. A comparative study based on NMR conformational analysis in solution and theoretical calculations.
Alvarez R; Jimeno ML; Gago F; Balzarini J; Pérez-Pérez MJ; Camarasa MJ
Antivir Chem Chemother; 1998 Jul; 9(4):333-40. PubMed ID: 9875412
[TBL] [Abstract][Full Text] [Related]
26. Novel benzophenones as non-nucleoside reverse transcriptase inhibitors of HIV-1.
Chan JH; Freeman GA; Tidwell JH; Romines KR; Schaller LT; Cowan JR; Gonzales SS; Lowell GS; Andrews CW; Reynolds DJ; St Clair M; Hazen RJ; Ferris RG; Creech KL; Roberts GB; Short SA; Weaver K; Koszalka GW; Boone LR
J Med Chem; 2004 Feb; 47(5):1175-82. PubMed ID: 14971897
[TBL] [Abstract][Full Text] [Related]
27. Synthesis and studies of new 2-(coumarin-4-yloxy)-4,6-(substituted)-S-triazine derivatives as potential anti-HIV agents.
Mahajan DH; Pannecouque C; De Clercq E; Chikhalia KH
Arch Pharm (Weinheim); 2009 May; 342(5):281-90. PubMed ID: 19415671
[TBL] [Abstract][Full Text] [Related]
28. Novel N-3 substituted TSAO-T derivatives: synthesis and anti-HIV-evaluation.
Bonache MC; Quesada E; Sheen CW; Balzarini J; Sluis-Cremer N; Pérez-Pérez MJ; Camarasa MJ; San-Félix A
Nucleosides Nucleotides Nucleic Acids; 2008 Apr; 27(4):351-67. PubMed ID: 18404570
[TBL] [Abstract][Full Text] [Related]
29. In vitro selection of mutations in human immunodeficiency virus type 1 reverse transcriptase that confer resistance to capravirine, a novel nonnucleoside reverse transcriptase inhibitor.
Sato A; Hammond J; Alexander TN; Graham JP; Binford S; Sugita K; Sugimoto H; Fujiwara T; Patick AK
Antiviral Res; 2006 Jun; 70(2):66-74. PubMed ID: 16472877
[TBL] [Abstract][Full Text] [Related]
30. Pyrimidine thioethers: a novel class of HIV-1 reverse transcriptase inhibitors with activity against BHAP-resistant HIV.
Nugent RA; Schlachter ST; Murphy MJ; Cleek GJ; Poel TJ; Wishka DG; Graber DR; Yagi Y; Keiser BJ; Olmsted RA; Kopta LA; Swaney SM; Poppe SM; Morris J; Tarpley WG; Thomas RC
J Med Chem; 1998 Sep; 41(20):3793-803. PubMed ID: 9748354
[TBL] [Abstract][Full Text] [Related]
31. N-3 substituted TSAO derivatives as a probe to explore the dimeric interface of HIV-1 reverse transcriptase.
Bonache MC; Chamorro C; Velázquez S; De Clercq E; Balzarini J; Camarasa MJ; San-Félix A
Nucleosides Nucleotides Nucleic Acids; 2003; 22(5-8):947-9. PubMed ID: 14565318
[No Abstract] [Full Text] [Related]
32. Potential multifunctional inhibitors of HIV-1 reverse transcriptase. Novel [AZT]-[TSAO-T] and [d4T]-[TSAO-T] heterodimers modified in the linker and in the dideoxynucleoside region.
Velázquez S; Tuñón V; Jimeno ML; Chamorro C; De Clercq E; Balzarini J; Camarasa MJ
J Med Chem; 1999 Dec; 42(25):5188-96. PubMed ID: 10602704
[TBL] [Abstract][Full Text] [Related]
33. Non-nucleoside HIV-1 reverse transcriptase inhibitors di-halo-indolyl aryl sulfones achieve tight binding to drug-resistant mutants by targeting the enzyme-substrate complex.
Samuele A; Kataropoulou A; Viola M; Zanoli S; La Regina G; Piscitelli F; Silvestri R; Maga G
Antiviral Res; 2009 Jan; 81(1):47-55. PubMed ID: 18984007
[TBL] [Abstract][Full Text] [Related]
34. Computational analysis of aza analogues of [2',5'-bis-O-(tert-butyldimethylsilyl)-beta-D-ribofuranose]-3'-spiro-5"-(4"-amino-1",2"-oxathiole-2",2"-dioxide) (TSAO) as HIV-1 reverse transcriptase inhibitors: relevance of conformational properties on the inhibitory activity.
Soriano E; Marco-Contelles J; Tomassi C; Nguyen Van Nhien A; Postel D
J Chem Inf Model; 2006; 46(4):1666-77. PubMed ID: 16859298
[TBL] [Abstract][Full Text] [Related]
35. Nitroimidazoles. V. Synthesis and anti-HIV evaluation of new 5-substituted piperazinyl-4-nitroimidazole derivatives.
Al-Soud YA; Al-Masoudi NA; Hassan HG; De Clercq E; Pannecouque C
Acta Pharm; 2007 Dec; 57(4):379-93. PubMed ID: 18165184
[TBL] [Abstract][Full Text] [Related]
36. The phenylmethylthiazolylthiourea nonnucleoside reverse transcriptase (RT) inhibitor MSK-076 selects for a resistance mutation in the active site of human immunodeficiency virus type 2 RT.
Auwerx J; Stevens M; Van Rompay AR; Bird LE; Ren J; De Clercq E; Oberg B; Stammers DK; Karlsson A; Balzarini J
J Virol; 2004 Jul; 78(14):7427-37. PubMed ID: 15220416
[TBL] [Abstract][Full Text] [Related]
37. Specific targeting highly conserved residues in the HIV-1 reverse transcriptase primer grip region. Design, synthesis, and biological evaluation of novel, potent, and broad spectrum NNRTIs with antiviral activity.
Fattorusso C; Gemma S; Butini S; Huleatt P; Catalanotti B; Persico M; De Angelis M; Fiorini I; Nacci V; Ramunno A; Rodriquez M; Greco G; Novellino E; Bergamini A; Marini S; Coletta M; Maga G; Spadari S; Campiani G
J Med Chem; 2005 Nov; 48(23):7153-65. PubMed ID: 16279773
[TBL] [Abstract][Full Text] [Related]
38. 4-Benzyl and 4-benzoyl-3-dimethylaminopyridin-2(1H)-ones: in vitro evaluation of new C-3-amino-substituted and C-5,6-alkyl-substituted analogues against clinically important HIV mutant strains.
Benjahad A; Croisy M; Monneret C; Bisagni E; Mabire D; Coupa S; Poncelet A; Csoka I; Guillemont J; Meyer C; Andries K; Pauwels R; de Béthune MP; Himmel DM; Das K; Arnold E; Nguyen CH; Grierson DS
J Med Chem; 2005 Mar; 48(6):1948-64. PubMed ID: 15771439
[TBL] [Abstract][Full Text] [Related]
39. Differences in the inhibition of human immunodeficiency virus type 1 reverse transcriptase DNA polymerase activity by analogs of nevirapine and [2',5'-bis-O-(tert-butyldimethylsilyl)-3'-spiro-5"-(4"-amino-1", 2"-oxathiole-2",2"-dioxide] (TSAO).
Arion D; Fletcher RS; Borkow G; Camarasa MJ; Balzarini J; Dmitrienko GI; Parniak MA
Mol Pharmacol; 1996 Nov; 50(5):1057-64. PubMed ID: 8913335
[TBL] [Abstract][Full Text] [Related]
40. TSAO-T analogues bearing amino acids at position N-3 of thymine: synthesis and anti-human immunodeficiency virus activity.
Chamorro C; De Clercq E; Balzarini J; Camarasa MJ; San-Félix A
Antivir Chem Chemother; 2000 Jan; 11(1):61-9. PubMed ID: 10693655
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
